All lobbying filings

Caris Life Sciences, Inc.

Caris Life Sciences, Inc. filed a Q3 report for Caris Life Sciences, Inc. on October 20, 2026.

Lobbying for Caris Life Sciences, Inc.

As filed: CARIS LIFE SCIENCES, INC. for CARIS LIFE SCIENCES, INC.

All filings by Caris Life Sciences, Inc. · Everything Caris Life Sciences, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$160,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Texas

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Medicare/Medicaid

Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); and appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting.

Health Issues

Role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags; Medicare payment for Software as a Medical Service (SaMS)

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.